These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12543656)

  • 1. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.
    Vinks AA; Den Hollander JG; Overbeek SE; Jelliffe RW; Mouton JW
    Antimicrob Agents Chemother; 2003 Feb; 47(2):541-7. PubMed ID: 12543656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
    Bulitta JB; Duffull SB; Kinzig-Schippers M; Holzgrabe U; Stephan U; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2497-507. PubMed ID: 17485505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM; Lodise TP; Beegle S; Rosen J; Farkas J; Pai MP
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.
    Vinks AA; Mouton JW; Touw DJ; Heijerman HG; Danhof M; Bakker W
    Antimicrob Agents Chemother; 1996 May; 40(5):1091-7. PubMed ID: 8723446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion.
    Dhaese SAM; Colin P; Willems H; Heffernan A; Gadeyne B; Van Vooren S; Depuydt P; Hoste E; Stove V; Verstraete AG; Lipman J; Roberts JA; De Waele JJ
    Int J Antimicrob Agents; 2019 Dec; 54(6):741-749. PubMed ID: 31479741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of intravenous piperacillin administration in patients undergoing on-line hemodiafiltration.
    Oh KH; Kim C; Lee H; Lee H; Jung JY; Kim NJ; Yu KS; Shin KH; Jang IJ; Ahn C
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3266-8. PubMed ID: 19451284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients.
    Manley HJ; Bailie GR; Frye R; McGoldrick MD
    Perit Dial Int; 2000; 20(6):686-93. PubMed ID: 11216560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
    Cies JJ; Jain J; Kuti JL
    Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.
    Lodise TP; Lomaestro B; Rodvold KA; Danziger LH; Drusano GL
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4718-24. PubMed ID: 15561849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.
    Nau R; Kinzig-Schippers M; Sörgel F; Schinschke S; Rössing R; Müller C; Kolenda H; Prange HW
    Antimicrob Agents Chemother; 1997 May; 41(5):987-91. PubMed ID: 9145857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimens.
    Bulitta JB; Kinzig M; Jakob V; Holzgrabe U; Sörgel F; Holford NH
    Br J Clin Pharmacol; 2010 Nov; 70(5):682-93. PubMed ID: 21039762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.